What is the P/E ratio of Bioter 2024?
The P/E ratio cannot be calculated for Bioter at the moment.
Access the world's leading financial data and tools
Subscribe for $2 
Overview
Profile
Bioter stock stock price, forecast, news, chart, split, dividend and analysis Bioter ariva, Bioter onvista, Bioter finanzen.net, Bioter aktienfinder, Bioter marketscreener, Bioter marketwatch, Bioter bloomberg, Bioter handelsblatt, Bioter wiwo, Bioter forum
BIOT.AT
GRS135003002
Price
Price
0.32
Today +/-
+0.03
Today %
+8.47 %
TickerBIOT.AT
ISINGRS135003002
P
Bioter stock price
%
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the Bioter stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the Bioter stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the Bioter stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze Bioter's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
Bioter Stock Price History
| Date | Bioter Price |
|---|---|
| 11/15/2024 | 0.32 undefined |
| 11/11/2024 | 0.29 undefined |
| 11/8/2024 | 0.29 undefined |
| 11/7/2024 | 0.27 undefined |
| 11/5/2024 | 0.29 undefined |
| 11/4/2024 | 0.29 undefined |
| 11/1/2024 | 0.29 undefined |
| 10/31/2024 | 0.33 undefined |
| 10/29/2024 | 0.33 undefined |
| 10/25/2024 | 0.32 undefined |
| 10/24/2024 | 0.36 undefined |
| 10/23/2024 | 0.35 undefined |
| 10/22/2024 | 0.33 undefined |
| 10/21/2024 | 0.30 undefined |
| 10/18/2024 | 0.30 undefined |
Bioter Revenue, EBIT, Net Income GRS135003002 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Bioter, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bioter from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bioter’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Bioter. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Bioter’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Bioter’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bioter’s growth potential.
Bioter Revenue, EBIT and net profit per share
| Date | Bioter Revenue | Bioter EBIT | Bioter Net Income |
|---|---|---|---|
| 2023 | 499,000 undefined | -2.1 M undefined | -11.68 M undefined |
| 2022 | 252,000 undefined | -1.41 M undefined | -9.68 M undefined |
| 2021 | 246,000 undefined | -1.05 M undefined | -8.81 M undefined |
| 2020 | 228,000 undefined | 16.19 M undefined | 6.06 M undefined |
| 2019 | 250,000 undefined | -4.35 M undefined | -8.89 M undefined |
| 2018 | 177,000 undefined | -5.82 M undefined | -12.8 M undefined |
| 2017 | 180,000 undefined | -6.65 M undefined | -17.52 M undefined |
| 2016 | 551,000 undefined | -5.92 M undefined | -18.33 M undefined |
| 2015 | 1.23 M undefined | -2.03 M undefined | -10.17 M undefined |
| 2014 | 4.95 M undefined | -3.58 M undefined | -13.52 M undefined |
| 2013 | 4.78 M undefined | -6.56 M undefined | -13.72 M undefined |
| 2012 | 6.36 M undefined | -33.53 M undefined | -35.81 M undefined |
| 2011 | 18.6 M undefined | -7.59 M undefined | -16.45 M undefined |
| 2010 | 37.88 M undefined | -18.85 M undefined | -14.45 M undefined |
| 2009 | 57.93 M undefined | 2.58 M undefined | -3.05 M undefined |
| 2008 | 67.14 M undefined | 7.41 M undefined | 460,000 undefined |
| 2007 | 72.55 M undefined | 7.78 M undefined | 1.51 M undefined |
| 2006 | 77.94 M undefined | 8.41 M undefined | 1.21 M undefined |
| 2005 | 75.7 M undefined | 5.31 M undefined | 260,000 undefined |
| 2004 | 78.92 M undefined | 8.61 M undefined | 6.92 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 78.92 M EUR | 8.61 M EUR | 6.92 M EUR |
| 2005 | 75.7 M EUR | 5.31 M EUR | 260,000 EUR |
| 2006 | 77.94 M EUR | 8.41 M EUR | 1.21 M EUR |
| 2007 | 72.55 M EUR | 7.78 M EUR | 1.51 M EUR |
| 2008 | 67.14 M EUR | 7.41 M EUR | 460,000 EUR |
| 2009 | 57.93 M EUR | 2.58 M EUR | -3.05 M EUR |
| 2010 | 37.88 M EUR | -18.85 M EUR | -14.45 M EUR |
| 2011 | 18.6 M EUR | -7.59 M EUR | -16.45 M EUR |
| 2012 | 6.36 M EUR | -33.53 M EUR | -35.81 M EUR |
| 2013 | 4.78 M EUR | -6.56 M EUR | -13.72 M EUR |
| 2014 | 4.95 M EUR | -3.58 M EUR | -13.52 M EUR |
| 2015 | 1.23 M EUR | -2.03 M EUR | -10.17 M EUR |
| 2016 | 551,000 EUR | -5.92 M EUR | -18.33 M EUR |
| 2017 | 180,000 EUR | -6.65 M EUR | -17.52 M EUR |
| 2018 | 177,000 EUR | -5.82 M EUR | -12.8 M EUR |
| 2019 | 250,000 EUR | -4.35 M EUR | -8.89 M EUR |
| 2020 | 228,000 EUR | 16.19 M EUR | 6.06 M EUR |
| 2021 | 246,000 EUR | -1.05 M EUR | -8.81 M EUR |
| 2022 | 252,000 EUR | -1.41 M EUR | -9.68 M EUR |
| 2023 | 499,000 EUR | -2.1 M EUR | -11.68 M EUR |
Bioter Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56 | 87 | 78 | 75 | 77 | 72 | 67 | 57 | 37 | 18 | 6 | 4 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| - | 55.36 | -10.34 | -3.85 | 2.67 | -6.49 | -6.94 | -14.93 | -35.09 | -51.35 | -66.67 | -33.33 | - | -75.00 | - | - | - | - | - | - | - | - |
| 26.79 | 14.94 | 19.23 | 17.33 | 15.58 | 12.50 | 5.97 | 12.28 | -35.14 | -22.22 | -450.00 | -175.00 | -100.00 | -200.00 | - | - | - | - | - | - | - | - |
| 15 | 13 | 15 | 13 | 12 | 9 | 4 | 7 | -13 | -4 | -27 | -7 | -4 | -2 | -5 | -6 | -4 | -3 | -1 | 0 | 0 | 0 |
| 5 | 6 | 6 | 0 | 1 | 1 | 0 | -3 | -14 | -16 | -35 | -13 | -13 | -10 | -18 | -17 | -12 | -8 | 6 | -8 | -9 | -11 |
| - | 20.00 | - | - | - | - | - | - | 366.67 | 14.29 | 118.75 | -62.86 | - | -23.08 | 80.00 | -5.56 | -29.41 | -33.33 | -175.00 | -233.33 | 12.50 | 22.22 |
| 16.3 | 16.3 | 16.3 | 14.57 | 13.64 | 17.35 | 17.02 | 16.73 | 48.37 | 16.73 | 16.73 | 16.73 | 16.73 | 16.73 | 16.73 | 16.73 | 16.73 | 16.73 | 16.73 | 16.73 | 16.73 | 16.73 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The Bioter Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Bioter is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
Bioter stock margins GRS135003002 ·
The Bioter margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bioter. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bioter.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Bioter's sales revenue. A higher gross margin percentage indicates that the Bioter retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Bioter's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Bioter's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bioter's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bioter. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bioter's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Bioter Margin History
| Bioter Gross margin | Bioter Profit margin | Bioter EBIT margin | Bioter Profit margin |
|---|---|---|---|
| 2023 | -9.62 % | -421.04 % | -2,340.88 % |
| 2022 | -5.95 % | -557.54 % | -3,840.08 % |
| 2021 | -380.08 % | -428.05 % | -3,580.89 % |
| 2020 | -637.72 % | 7,100.88 % | 2,656.58 % |
| 2019 | -1,494 % | -1,739.6 % | -3,556.4 % |
| 2018 | -2,820.34 % | -3,289.27 % | -7,229.38 % |
| 2017 | -3,601.67 % | -3,695 % | -9,730.56 % |
| 2016 | -944.65 % | -1,074.77 % | -3,325.77 % |
| 2015 | -184.27 % | -165.53 % | -829.1 % |
| 2014 | -81.4 % | -72.28 % | -273.31 % |
| 2013 | -150.21 % | -137.24 % | -287.03 % |
| 2012 | -433.18 % | -527.2 % | -563.05 % |
| 2011 | -24.57 % | -40.81 % | -88.44 % |
| 2010 | -34.53 % | -49.76 % | -38.15 % |
| 2009 | 13.12 % | 4.45 % | -5.26 % |
| 2008 | 6.72 % | 11.04 % | 0.69 % |
| 2007 | 12.54 % | 10.72 % | 2.08 % |
| 2006 | 16.11 % | 10.79 % | 1.55 % |
| 2005 | 18.34 % | 7.01 % | 0.34 % |
| 2004 | 19.06 % | 10.91 % | 8.77 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 19.06 % | 10.91 % | 8.77 % |
| 2005 | 18.34 % | 7.01 % | 0.34 % |
| 2006 | 16.11 % | 10.79 % | 1.55 % |
| 2007 | 12.54 % | 10.72 % | 2.08 % |
| 2008 | 6.72 % | 11.04 % | 0.69 % |
| 2009 | 13.12 % | 4.45 % | -5.26 % |
| 2010 | -34.53 % | -49.76 % | -38.15 % |
| 2011 | -24.57 % | -40.81 % | -88.44 % |
| 2012 | -433.18 % | -527.2 % | -563.05 % |
| 2013 | -150.21 % | -137.24 % | -287.03 % |
| 2014 | -81.4 % | -72.28 % | -273.31 % |
| 2015 | -184.27 % | -165.53 % | -829.1 % |
| 2016 | -944.65 % | -1,074.77 % | -3,325.77 % |
| 2017 | -3,601.67 % | -3,695 % | -9,730.56 % |
| 2018 | -2,820.34 % | -3,289.27 % | -7,229.38 % |
| 2019 | -1,494 % | -1,739.6 % | -3,556.4 % |
| 2020 | -637.72 % | 7,100.88 % | 2,656.58 % |
| 2021 | -380.08 % | -428.05 % | -3,580.89 % |
| 2022 | -5.95 % | -557.54 % | -3,840.08 % |
| 2023 | -9.62 % | -421.04 % | -2,340.88 % |
Bioter Stock Sales Revenue, EBIT, Earnings per Share GRS135003002 ·
The Bioter earnings per share therefore indicates how much revenue Bioter has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Bioter earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Bioter's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Bioter’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bioter's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Bioter Revenue, EBIT and net profit per share
| Date | Bioter Sales per Share | Bioter EBIT per share | Bioter Earnings per Share |
|---|---|---|---|
| 2023 | 0.03 undefined | -0.13 undefined | -0.7 undefined |
| 2022 | 0.02 undefined | -0.08 undefined | -0.58 undefined |
| 2021 | 0.01 undefined | -0.06 undefined | -0.53 undefined |
| 2020 | 0.01 undefined | 0.97 undefined | 0.36 undefined |
| 2019 | 0.01 undefined | -0.26 undefined | -0.53 undefined |
| 2018 | 0.01 undefined | -0.35 undefined | -0.76 undefined |
| 2017 | 0.01 undefined | -0.4 undefined | -1.05 undefined |
| 2016 | 0.03 undefined | -0.35 undefined | -1.1 undefined |
| 2015 | 0.07 undefined | -0.12 undefined | -0.61 undefined |
| 2014 | 0.3 undefined | -0.21 undefined | -0.81 undefined |
| 2013 | 0.29 undefined | -0.39 undefined | -0.82 undefined |
| 2012 | 0.38 undefined | -2 undefined | -2.14 undefined |
| 2011 | 1.11 undefined | -0.45 undefined | -0.98 undefined |
| 2010 | 0.78 undefined | -0.39 undefined | -0.3 undefined |
| 2009 | 3.46 undefined | 0.15 undefined | -0.18 undefined |
| 2008 | 3.94 undefined | 0.44 undefined | 0.03 undefined |
| 2007 | 4.18 undefined | 0.45 undefined | 0.09 undefined |
| 2006 | 5.71 undefined | 0.62 undefined | 0.09 undefined |
| 2005 | 5.2 undefined | 0.36 undefined | 0.02 undefined |
| 2004 | 4.84 undefined | 0.53 undefined | 0.42 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2004 | 4.84 EUR | 0.53 EUR | 0.42 EUR |
| 2005 | 5.2 EUR | 0.36 EUR | 0.02 EUR |
| 2006 | 5.71 EUR | 0.62 EUR | 0.09 EUR |
| 2007 | 4.18 EUR | 0.45 EUR | 0.09 EUR |
| 2008 | 3.94 EUR | 0.44 EUR | 0.03 EUR |
| 2009 | 3.46 EUR | 0.15 EUR | -0.18 EUR |
| 2010 | 0.78 EUR | -0.39 EUR | -0.3 EUR |
| 2011 | 1.11 EUR | -0.45 EUR | -0.98 EUR |
| 2012 | 0.38 EUR | -2 EUR | -2.14 EUR |
| 2013 | 0.29 EUR | -0.39 EUR | -0.82 EUR |
| 2014 | 0.3 EUR | -0.21 EUR | -0.81 EUR |
| 2015 | 0.07 EUR | -0.12 EUR | -0.61 EUR |
| 2016 | 0.03 EUR | -0.35 EUR | -1.1 EUR |
| 2017 | 0.01 EUR | -0.4 EUR | -1.05 EUR |
| 2018 | 0.01 EUR | -0.35 EUR | -0.76 EUR |
| 2019 | 0.01 EUR | -0.26 EUR | -0.53 EUR |
| 2020 | 0.01 EUR | 0.97 EUR | 0.36 EUR |
| 2021 | 0.01 EUR | -0.06 EUR | -0.53 EUR |
| 2022 | 0.02 EUR | -0.08 EUR | -0.58 EUR |
| 2023 | 0.03 EUR | -0.13 EUR | -0.7 EUR |
Bioter business model
Bioter is one of the most popular companies on Eulerpool.com.
Bioter Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
Bioter historical P/E ratio, EBIT multiple, and P/S ratio
Bioter shares outstanding GRS135003002 ·
The number of shares was Bioter in 2023 — This indicates how many shares 16.735 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Bioter earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Bioter's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Bioter’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bioter's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 16.3 M Aktien |
| 2005 | 14.57 M Aktien |
| 2006 | 13.64 M Aktien |
| 2007 | 17.35 M Aktien |
| 2008 | 17.02 M Aktien |
| 2009 | 16.73 M Aktien |
| 2010 | 48.37 M Aktien |
| 2011 | 16.73 M Aktien |
| 2012 | 16.73 M Aktien |
| 2013 | 16.73 M Aktien |
| 2014 | 16.73 M Aktien |
| 2015 | 16.73 M Aktien |
| 2016 | 16.73 M Aktien |
| 2017 | 16.73 M Aktien |
| 2018 | 16.73 M Aktien |
| 2019 | 16.73 M Aktien |
| 2020 | 16.73 M Aktien |
| 2021 | 16.73 M Aktien |
| 2022 | 16.73 M Aktien |
| 2023 | 16.73 M Aktien |
Bioter stock splits
In Bioter's history, there have been no stock splits.
Bioter dividend history and estimates GRS135003002 ·
In 2023, Bioter paid a dividend amounting to 0 EUR. Dividend means that Bioter distributes a portion of its profits to its owners.
3 years
5 years
10 years
25 Years
Max
Dividend
Dividend (Estimate)
Details
Dividend
ⓘDividend Overview
The dividend per year chart for Bioter provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.
Interpretation and Use
A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Bioter’s potential for long-term investment and income generation through dividends.
Investment Strategy
Incorporate the dividend data in evaluating Bioter's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.
Bioter Dividend History
| Date | Bioter Dividend |
|---|---|
| 2006 | 0.07 undefined |
| 2005 | 0.16 undefined |
| 2004 | 0.11 undefined |
| Dividend | Dividend (Estimate) | |
|---|---|---|
| 2004 | 0.11 EUR | 0 EUR |
| 2005 | 0.16 EUR | 0 EUR |
| 2006 | 0.07 EUR | 0 EUR |
| 2007 | 0 EUR | 0 EUR |
| 2008 | 0 EUR | 0 EUR |
| 2009 | 0 EUR | 0 EUR |
| 2010 | 0 EUR | 0 EUR |
| 2011 | 0 EUR | 0 EUR |
| 2012 | 0 EUR | 0 EUR |
| 2013 | 0 EUR | 0 EUR |
| 2014 | 0 EUR | 0 EUR |
| 2015 | 0 EUR | 0 EUR |
| 2016 | 0 EUR | 0 EUR |
| 2017 | 0 EUR | 0 EUR |
| 2018 | 0 EUR | 0 EUR |
| 2019 | 0 EUR | 0 EUR |
| 2020 | 0 EUR | 0 EUR |
| 2021 | 0 EUR | 0 EUR |
| 2022 | 0 EUR | 0 EUR |
| 2023 | 0 EUR | 0 EUR |
Bioter dividend payout ratio GRS135003002 ·
In 2023, Bioter had a payout ratio of 310.4%. The payout ratio indicates the percentage of the company's profits that Bioter distributes as dividends.
3 years
5 years
10 years
25 Years
Max
Payout ratio
Details
Payout ratio
ⓘWhat is Yearly Payout Ratio?
The yearly payout ratio for Bioter represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.
How to Interpret the Data
A lower payout ratio for Bioter could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.
Using the Data for Investments
Evaluate Bioter's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.
Bioter Payout Ratio History
| Date | Bioter Payout ratio |
|---|---|
| 2023 | 310.4 % |
| 2022 | 310.46 % |
| 2021 | 310.35 % |
| 2020 | 310.4 % |
| 2019 | 310.62 % |
| 2018 | 310.04 % |
| 2017 | 310.54 % |
| 2016 | 311.27 % |
| 2015 | 308.33 % |
| 2014 | 312.02 % |
| 2013 | 313.46 % |
| 2012 | 299.51 % |
| 2011 | 323.1 % |
| 2010 | 317.76 % |
| 2009 | 257.66 % |
| 2008 | 393.87 % |
| 2007 | 301.77 % |
| 2006 | 77.33 % |
| 2005 | 802.5 % |
| 2004 | 25.48 % |
| Payout ratio | |
|---|---|
| 2004 | 25.48 % |
| 2005 | 802.5 % |
| 2006 | 77.33 % |
| 2007 | 301.77 % |
| 2008 | 393.87 % |
| 2009 | 257.66 % |
| 2010 | 317.76 % |
| 2011 | 323.1 % |
| 2012 | 299.51 % |
| 2013 | 313.46 % |
| 2014 | 312.02 % |
| 2015 | 308.33 % |
| 2016 | 311.27 % |
| 2017 | 310.54 % |
| 2018 | 310.04 % |
| 2019 | 310.62 % |
| 2020 | 310.4 % |
| 2021 | 310.35 % |
| 2022 | 310.46 % |
| 2023 | 310.4 % |
Unfortunately, there are currently no price targets and forecasts available for Bioter.
Bioter shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 18.61470 % | Mavroskotis (Georgios A) | 3,115,132 | 0 | 7/25/2024 |
| 14.51148 % | Antonia (Katsarou) | 2,428,467 | 0 | 7/25/2024 |
| 5.43734 % | Andreas (Mavroskotis) | 909,928 | 0 | 7/25/2024 |
| 5.28817 % | Comair (Christian) | 884,965 | 0 | 7/25/2024 |
| 5.27556 % | Antonios (Mavroskotis) | 882,855 | 0 | 7/25/2024 |
1
Most common questions regarding Bioter
What is the P/S ratio of Bioter 2024?
The P/S cannot be calculated for Bioter currently.
What is the Quality Investing of Bioter?
The Quality Investing for Bioter is 2/10.
What is the revenue of Bioter 2024?
The revenue cannot currently be calculated for Bioter.
How high is the profit of Bioter 2024?
The profit cannot currently be calculated for Bioter.
What is the business model of Bioter
No history available for Bioter.
What is the Bioter dividend?
Bioter pays a dividend of 0 EUR distributed over payouts per year.
How often does Bioter pay dividends?
The dividend cannot currently be calculated for Bioter or the company does not pay out a dividend.
What is the Bioter ISIN?
The ISIN of Bioter is GRS135003002.
What is the Bioter ticker?
The ticker of Bioter is BIOT.AT.
How much dividend does Bioter pay?
Over the past 12 months, Bioter paid a dividend of 0.07 EUR . This corresponds to a dividend yield of about 21.75 %. For the coming 12 months, Bioter is expected to pay a dividend of 0 EUR.
What is the dividend yield of Bioter?
The current dividend yield of Bioter is 21.75 %.
When does Bioter pay dividends?
Bioter pays a quarterly dividend. This is distributed in the months of August, August, August, September.
How secure is the dividend of Bioter?
Bioter paid dividends every year for the past 0 years.
What is the dividend of Bioter?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Bioter located?
Bioter is assigned to the 'Industry' sector.
Wann musste ich die Aktien von Bioter kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Bioter from 8/28/2006 amounting to 0.02 EUR, you needed to have the stock in your portfolio before the ex-date on 8/18/2006.
When did Bioter pay the last dividend?
The last dividend was paid out on 8/28/2006.
What was the dividend of Bioter in the year 2023?
In the year 2023, Bioter distributed 0 EUR as dividends.
In which currency does Bioter pay out the dividend?
The dividends of Bioter are distributed in EUR.
Bioter stock
Sector
Industry
Industry
Construction & Engineering
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website Bioter
Country
Greece 🇬🇷
Currency
EUR
Initial public offering
Aug 27, 1975
GOSIN
Global Open Securities Identification Number
Cusip
X97922144
Market capitalization
Quality Investing
2 / 10Details
PEG
0
P/E ratio
Forward P/E ratio
0
P/S ratio
Forward P/S ratio
0
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
Bioter Peer Group
Bioter Eulerpool News
Bioter News
Bioter Ticker
| Stock Exchange | Bioter Ticker |
|---|---|
| ATHENS | BIOT.AT |
| ATHENS | BIOT.AT |
| LONDON | 0P0F.L |
Bioter FIGI
| Bioter Ticker | Bioter FIGI |
|---|---|
| BIOT:GA | BBG000DKDYH3 |
| BIOT1:EO | BBG000QVLS25 |
| BIOT1:XH | BBG000QVLV46 |
| BIOT1:XC | BBG000QVLVL7 |
| BIOT1:XF | BBG000QVLVV6 |
| BIOT1:XE | BBG000QVLXH8 |
| BIOT1:XJ | BBG000QVLXN1 |
| BIOT1:XL | BBG000QVLZC8 |
| BIOT1:XG | BBG000QVLZV7 |
| BIOT1:XO | BBG000QVM052 |
| BIOT1:XS | BBG000QVM212 |
| BIOT1:XA | BBG000QVM267 |
| BIOT1:E1 | BBG000QVM2D9 |
| BIOT1:XT | BBG000QVM2K1 |
| BIOT1:XW | BBG000QVM2N8 |
| BIOT1:EU | BBG000QVM3J1 |
| BIOT1:XV | BBG00591HX23 |
| BIOTY:B3 | BBG006T7CRK4 |
| BIOTY:L3 | BBG006TBG9B1 |
| BIOTY:PO | BBG008GZD146 |
| BIOT1:XX | BBG00JN7FK06 |
| BIOTY:L1 | BBG00Y7BH166 |
| 0P0F:LN | BBG012GNTVF0 |
| BIOT1CAD:XS | BBG0155VXQR0 |
| BIOT1CAD:X2 | BBG0155VXQS9 |
| BIOT1CAD:XH | BBG0155VXQV5 |
| BIOT1CAD:XF | BBG0155VXQX3 |
| BIOT1CAD:XE | BBG0155VXQZ1 |
| BIOT1CAD:XJ | BBG0155VXR07 |
| BIOT1CAD:XL | BBG0155VXR16 |
| BIOT1CAD:XG | BBG0155VXR25 |
| BIOT1CAD:XO | BBG0155VXR34 |
| BIOT1CAD:XA | BBG0155VXR70 |
| BIOT1CAD:E1 | BBG0155VXR89 |
| BIOT1CAD:XT | BBG0155VXR98 |
| BIOT1CAD:XW | BBG0155VXRB5 |
| BIOT1CAD:XU | BBG0155VXRC4 |
| BIOT1CAD:XV | BBG0155VXRF1 |
| BIOT1CAD:XM | BBG0155VXRG0 |
| BIOT1CAD:XQ | BBG0155VXRH9 |
| BIOT1CAD:XX | BBG0155VXRJ7 |
| BIOT1CAD:XZ | BBG0155VXRK5 |
| BIOT1CAD:X1 | BBG0155VXRM3 |
| BIOT1CAD:EU | BBG0155VXRP0 |
| JV8:GR | BBG019VHZ8B9 |
| JV8:LA | BBG019VHZ8S1 |
| JV8:LU | BBG019VHZ8T0 |
All fundamentals about Bioter
Our stock analysis for Bioter Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bioter Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.